Satellos Bioscience Inc. (MSLE)
NASDAQ: MSLE · Real-Time Price · USD
6.44
-0.02 (-0.31%)
At close: Oct 19, 2026, 4:00 PM EDT
6.44
0.00 (0.00%)
After-hours: Oct 19, 2026, 4:10 PM EDT
Satellos Bioscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
138.25M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 77.68M |
| Atrium Therapeutics | 35.84M |
| Innate Pharma | 11.21M |
| Adagene | 9.29M |
| Molecular Partners AG | 856.30K |
MSLE News
- 11 days ago - Craig-Hallum initiates Satellos with a Buy ahead of BASECAMP data - TheFly
- 11 days ago - Satellos initiated with a Buy at Craig-Hallum - TheFly
- 14 days ago - Satellos granted composition of matter patent for forazapadin - TheFly
- 14 days ago - Satellos Granted Composition of Matter Patent for Forazapadin - Financial Post
- 14 days ago - Satellos Granted Composition of Matter Patent for Forazapadin - GlobeNewsWire
- 19 days ago - Satellos Completes Enrollment In Phase 2 Forazapadin Trial For DMD - Nasdaq
- 19 days ago - Satellos announces enrollment completed for BASECAMP - TheFly
- 19 days ago - Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy - Financial Post